Business Standard

Covid-19 throws up drug supply opportunity for Ipca, other pharma firms

Sun Pharma, Dr Reddy's, Torrent Pharma, Cipla, Cadila Healthcare and Natco Pharma would also benefit from malaria drug supplies, Alembic Pharma from azithromycin sales

coronavirus
Premium

Though Ipca as the largest supplier of anti-malarial drug stands to gain, there are other players who would also benefit.

Ujjval Jauhari
Ipca Laboratories, which climbed over 17 per cent intra-day to a fresh 52-week high, closed flat on Monday mainly due to the steep correction of over 13 per cent in leading indices. Sentiment on the street got a shot in the arm with US FDA making exceptions to its import alert for Ipca’s active pharma ingredients (API) and finished products of hydroxychloroquine sulphate and chloroquine phosphate. Anti-malarial drugs have been highlighted to have potential use in curing Covid-19.

The news is significantly positive for Ipca, which had been reeling under FDA import alerts for its manufacturing facilities since 2015. Analysts

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in